Central giant cell lesion of mandible managed by intralesional triamcinolone injections. A report of two cases and literature review.
Central giant cell lesion (CGCL) is a benign lesion which has unpredictable biologic behaviour and is amenable to a plethora of treatment alternatives. We describe our experience in managing this lesion by intralesional triamcinolone. The mainstay of treatment of CGCL in our centre until now has been surgical curettage or resection. We chose two patients for this pilot endeavour at our hands. Case I is a 10 year old girl having CGCL of left side mandible. Case II is a 20 yr old man with CGCL affecting the left side posterior mandible. Both patients responded well to intralesional administration of triamcinolone acetonide (Kenacort-10) with no obvious recurrences to date. Successful application of this conservative drug therapy for managing CGCL can not only save the patient from a mutilating procedure but also has significant financial implications. The amount of triamcinolone injected ranged from 85 mg to 180 mg by 5-6 injections at weekly intervals.
Mohanty
Sujata
S
Department of Oral & Maxillofacial Surgery, Maulana Azad Institute of Dental Sciences, New Delhi, India.
Jhamb
Aakarsh
A
D002648:Child; D005260:Female; D018212:Giant Cell Tumor of Bone / Q000188:drug therapy*; D005938:Glucocorticoids / Q000008:administration & dosage*; D006801:Humans; D015552:Injections, Intralesional; D008297:Male; D008339:Mandibular Neoplasms / Q000188:drug therapy*; D014222:Triamcinolone Acetonide / Q000008:administration & dosage*; D055815:Young Adult
D005938:Glucocorticoids; D014222:Triamcinolone Acetonide